---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-113524"
form_type: "8-K"
ticker: "SANA"
cik: "0001770121"
company_name: "Sana Biotechnology, Inc."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:10:36.371325+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Sana Biotechnology CFO Nathan Hardy resigns; CEO Harr named acting PFO, Susan Wyrick acting CFO

## Summary
- CFO Nathan Hardy resigned effective Oct 4, 2024; acting appointments made same day.
- CEO Steven D. Harr appointed acting Principal Financial Officer; no compensation change.
- Susan Wyrick appointed Acting CFO, Treasurer, and PAO; receives $5k/month extra, $25k bonus, 20,000 RSUs.
- Wyrick previously SVP Finance; former VP Controller at Juno Therapeutics prior to Celgene acquisition.

## SEC filing metadata
- accession: 0000950170-24-113524
- form_type: 8-K
- ticker: SANA
- cik: 0001770121
- company_name: Sana Biotechnology, Inc.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/0000950170-24-113524-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/sana-20241004.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-113524
- JSON: https://secwatch.observer/filing/0000950170-24-113524.json
- Plain text: https://secwatch.observer/filing/0000950170-24-113524.txt

## Key facts
- Executive change
  Nathan Hardy resigned as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer at Sana Biotechnology, Inc..
  - Action: resigned
  - Role: Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer, Principal Accounting Officer
  source text: Nathan Hardy’s resignation as Executive Vice President and Chief Financial Officer, Treasurer, Principal Financial Officer (“PFO”), and Principal Accounting Officer (“PAO”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/0000950170-24-113524-index.htm
- Executive change
  Susan Wyrick was appointed as Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer at Sana Biotechnology, Inc..
  - Action: appointed
  - Role: Acting Chief Financial Officer, Treasurer, and Principal Accounting Officer
  source text: Susan Wyrick, the Company’s Senior Vice President, Finance and Accounting, was appointed to serve as Acting Chief Financial Officer, Treasurer, and PAO
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/0000950170-24-113524-index.htm
- Executive change
  Steven D. Harr was appointed as acting Principal Financial Officer at Sana Biotechnology, Inc..
  - Action: appointed
  - Role: acting Principal Financial Officer
  source text: Steven D. Harr, M.D., the Company’s President and Chief Executive Officer, was appointed to serve as acting PFO in addition to his role as President and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1770121/000095017024113524/0000950170-24-113524-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.